Thursday 15 October 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
2.27
0.02
+0.89%
Follow ELDN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (236.51%) | (150.79%) | (63.56%) | (143.22%) |
+8 more TTM periods Free account |
|
| (72.74%) | (50.75%) | (26.34%) | (65.28%) | ||
ROIC |
0.00% | 0.00% | (1,511.24%) | 0.00% | |
Return on Tangible Assets |
(121.23%) | (78.06%) | (38.87%) | (97.30%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.65) | (0.61) | (0.76) | (0.87) | |
Free Cash Flow |
(73.86) | (68.89) | (62.34) | (67.24) | |
| Other line items | |||||
Cash ROIC |
(45.93%) | (32.57%) | (23.08%) | (36.45%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.75 | 0.88 | 1.37 | 0.84 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.65) | (0.61) | (0.76) | (0.87) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates